Gain’s lead program in Parkinson’s disease has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, ...

Gain Therapeutics (GANX) provided a letter to shareholders from the Company’s President and CEO, Gene Mack, which read in part,”With 2025 ...

BETHESDA, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company ...

Gain Therapeutics, Inc. (GANX), a pharmaceutical company currently trading at $2.14 per share with a market capitalization of $56.5 million, announced on Monday that it has regained compliance ...

After hours: February 3 at 6:30:56 PM EST Loading Chart for GANX ...

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Gain Therapeutics, Inc. before investing. In this article, we go over a few key ...

Gain Therapeutics, Inc. (GANX)是一家目前股价为每股2.14美元、市值5650万美元的制药公司，该公司周一宣布已重新符合纳斯达克的 ...